Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus Keytruda® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
Phase 3positiveIntismeran Autogene Plus KeytrudaKeytrudaPositive
AI Analysis
Summary
Merck and Moderna announced positive Phase 3 topline results from the INTerpath-001 trial showing that Intismeran Autogene Plus Keytruda met primary endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS)
Importance:8/10
Sentiment:
0.85
Phase 3 positivemelanomacombination therapypartnership
Read the original article
Published by Drugs.com Clinical Trial Results on August 19, 2026 10:08 PM